Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...
Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...
Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE- Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...
Milestones Include Top-Tier 3-Year Accreditations from OASAS and The Joint Commission, Staff Growth to Over 20 ...
Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 ...
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance ...
Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.
Indivior has also scheduled a shareholder vote for December 11, 2025, regarding a proposed re-domestication from the United Kingdom to Delaware, with relevant information distributed to shareholders.
Furthermore, research presented at the Academy of Managed Care Pharmacy Nexus 2025 conference highlighted that high adherence to SUBLOCADE results in significantly lower relapse rates and reduced ...
InvestorsHub on MSN
Indivior shares gain as FY26 outlook comes in ahead of market forecasts
Shares of Indivior (NASDAQ:INDV) climbed 4.5% in U.S. premarket trading on Thursday after the company issued fiscal 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback